Current Report Filing (8-k)
16 August 2022 - 7:10AM
Edgar (US Regulatory)
0001677077
false
0001677077
2022-08-15
2022-08-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
___________________________________________________________________
Date of Report (Date of earliest event reported): August
15, 2022
ALZAMEND NEURO, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40483 |
|
81-1822909 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326
(Address of principal executive offices) (Zip Code)
(844) 722-6333
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
|
ALZN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
| ITEM 7.01 | REGULATION FD DISCLOSURE |
Alzamend Neuro, Inc. (the “Company”) updated
its investor presentation (the “Corporate Presentation”), which is used
to conduct meetings with investors, stockholders and analysts and at investor conferences, which may contain nonpublic information. A
copy of the Corporate Presentation, which is furnished herewith as Exhibit 99.1, is incorporated by reference herein.
The Corporate Presentation provides, among other things, an overview of the Company’s therapeutic drugs for the treatment of neurodegenerative
diseases and psychiatric disorders, including Alzheimer’s.
In accordance with General Instruction B.2 of Form 8-K, the
information under this item and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission
as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
The Securities and Exchange Commission encourages registrants
to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and
reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among
other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,”
and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ
materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented within.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Corporate Presentation. |
101 |
|
Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALZAMEND NEURO, INC. |
|
|
|
|
|
|
Dated: August 15, 2022 |
/s/ Henry Nisser |
|
|
Henry Nisser |
|
|
Executive Vice President and General Counsel |
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Apr 2023 to Apr 2024